Form 4: Artivion CEO Exercises Options, Sells Shares

Artivion, Inc. President & CEO James P. Mackin exercised stock options and subsequently sold 30,921 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• James P. Mackin, President & CEO of Artivion, Inc., reported transactions on December 2, 2025.
• Exercised 30,921 stock options at an exercise price of $29.62 per share.
• Immediately sold 30,921 shares of common stock at a weighted average price of $45.559 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025.
• Following these transactions, Mackin directly beneficially owns 800,993 shares of Artivion common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an insider sale can sometimes be viewed negatively, the transaction was pre-planned under a 10b5-1 plan, indicating a non-discretionary sale for personal financial planning rather than a reaction to new negative information. The significant profit realized from the option exercise also reflects positively on the value creation for the executive.

Positives

• The transaction demonstrates the CEO's ability to realize value from previously granted stock options, indicating personal financial gain.
• The sale price of $45.559 is significantly higher than the exercise price of $29.62, reflecting a substantial profit on the exercised options.
• The transaction was conducted under a Rule 10b5-1 plan, suggesting a pre-planned and non-discretionary sale, which can mitigate concerns about opportunistic insider selling.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence or a signal that the stock price may be nearing a peak.
• The CEO's direct beneficial ownership decreased by 30,921 shares following the sale.

Risks

• Market perception risk: Investors might view the insider sale negatively, potentially leading to short-term downward pressure on the stock price.

Future Outlook

N/A

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a routine executive compensation event within the medical device industry.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan mitigates concerns. The reduction in direct insider ownership is minor relative to total shares outstanding.

Key Dates

Recommendation

The Form 4 filing details a routine insider transaction where the CEO exercised stock options and sold a portion of the resulting shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executive compensation and personal financial planning. While an insider sale can sometimes raise questions, the existence of a 10b5-1 plan suggests the decision was made in advance and not based on recent non-public information. The significant profit realized from the options indicates past stock performance. Without additional financial or operational context from other filings, this specific transaction alone does not warrant a 'buy' or 'sell' recommendation, but rather a 'hold' as it's a neutral event in the broader investment thesis.

Keywords

Artivion, AORT, Insider Trading, Form 4, Stock Options, CEO, Share Sale, 10b5-1 Plan, Executive Compensation